Requirement for cyclin D3 in lymphocyte development and T cell leukemias

Cancer Cell

Volumn 4, Issue 6, 2003, Pages 451-461

  Sicinska, Ewa ^a   Aifantis, Iannis ^b   Le Cam, Laurent ^a   Swat, Wojciech ^c   Borowski, Christine ^a   Yu, Qunyan ^a   Ferrando, Adolfo A ^a   Levin, Steven D ^d,e   Geng, Yan ^a   Von Boehmer, Harald ^a   Sicinski, Piotr ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e ZYMOGENETICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D3; NOTCH1 RECEPTOR; PROTEIN P56; SMALL INTERFERING RNA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; THYMOCYTE; WESTERN BLOTTING;

ANIMALIA; MAMMALIA;

EID: 9144229104     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00301-5     Document Type: Article

References (62)

1. Abraham K., Levin S., Marth J., Forbush K., Perlmutter R. Thymic tumorigenesis induced by overexpression of p56lck. Proc. Natl. Acad. Sci. USA. 88:1991;3977-3981.
2. Aifantis I., Borowski C., Gounari F., Lacorazza H., Nikolich-Zugich J., von Boehmer H. A critical role for the cytoplasmic tail of pTalpha in T lymphocyte development. Nat. Immunol. 3:2002;483-488.
3. Allman D., Karnell F., Punt J., Bakkour S., Xu L., Myung P., Koretzky G., Pui J., Aster J., Pear W. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J. Exp. Med. 194:2001;99-106.
4. Aster J., Xu L., Karnell F., Patriub V., Pui J., Pear W. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol. Cell. Biol. 20:2000;7505-7515.
5. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene. 10:1995;775-778.
6. Bartkova J., Lukas J., Strauss M., Bartek J. Cyclin D3. requirement for G1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation Oncogene. 17:1998;1027-1037.
7. Bates S., Bonetta L., MacAllan D., Parry D., Holder A., Dickson C., Peters G. CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene. 9:1994;71-79.
8. Bellavia D., Campese A., Alesse E., Vacca A., Felli M., Balestri A., Stoppacciaro A., Tiveron C., Tatangelo L., Giovarelli M.et al. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J. 19:2000;3337-3348.
9. Bellavia D., Campese A., Checquolo S., Balestri A., Biondi A., Cazzaniga G., Lendahl U., Fehling H., Hayday A., Frati L.et al. Combined expression of pTalpha and Notch3 in T cell leukemia identifies the requirement of preTCR for leukemogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;3788-3793.
10. Buschges R., Weber R., Actor B., Lichter P., Collins V., Reifenberger G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol. 9:1999;435-442. discussion 432-33.
11. Cheung T., Yu M., Lo K., Yim S., Chung T., Wong Y. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix. Cancer Lett. 166:2001;199-206.
12. Colucci F., Guy-Grand D., Wilson A., Turner M., Schweighoffer E., Tybulewicz V., Di Santo J. A new look at Syk in alpha beta and gamma delta T cell development using chimeric mice with a low competitive hematopoietic environment. J. Immunol. 164:2000;5140-5145.
13. Delmer A., Ajchenbaum-Cymbalista F., Tang R., Ramond S., Faussat A., Marie J., Zittoun R. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood. 85:1995;p2870-p2876.
14. Di Santo J., Radtke F., Rodewald H. To be or not to be a pro-T? Curr. Opin. Immunol. 12:2000;159-165.
15. Dickson C., Fantl V., Gillett C., Brookes S., Bartek J., Smith R., Fisher C., Barnes D., Peters G. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 90:1995;43-50.
16. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev. 12:1998;p2245-p2262.
17. Eisen M., Spellman P., Brown P., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. USA. 95:1998;14863-14868.
18. Engel I., Murre C. The function of E- and Id proteins in lymphocyte development. Nat. Rev. Immunol. 1:2001;193-199.
19. Fantl V., Stamp G., Andrews A., Rosewell I., Dickson C. Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9:1995;2364-2372.
20. Fehling H., Krotkova A., Saint-Ruf C., von Boehmer H. Crucial role of the pre-T-cell receptor alpha gene in development of alpha beta but not gamma delta T cells. Nature. 375:1995;795-798.
21. Fehling H., Iritani B., Krotkova A., Forbush K., Laplace C., Perlmutter R., von Boehmer H. Restoration of thymopoiesis in pT alpha-/- mice by anti-CD3epsilon antibody treatment or with transgenes encoding activated Lck or tailless pT alpha. Immunity. 6:1997;703-714.
22. Ferrando A., Neuberg D., Staunton J., Loh M., Huard C., Raimondi S., Behm F., Pui C., Downing J., Gilliland D.et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:2002;75-87.
23. Filipits M., Jaeger U., Pohl G., Stranzl T., Simonitsch I., Kaider A., Skrabs C., Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin. Cancer Res. 8:2002;729-733.
24. Fujii M., Ishiguro R., Yamashita T., Tashiro M. Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue. Cancer Lett. 172:2001;187-192.
25. Golub T., Slonim D., Tamayo P., Huard C., Gaasenbeek M., Mesirov J., Coller H., Loh M., Downing J., Caligiuri M.et al. Molecular classification of cancer. class discovery and class prediction by gene expression monitoring Science. 286:1999;531-537.
26. Hanke J., Gardner J., Dow R., Changelian P., Brissette W., Weringer E., Pollok B., Connelly P. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271:1996;695-701.
27. Hedberg Y., Roos G., Ljungberg B., Landberg G. Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta Oncol. 41:2002;175-181.
28. Hoffman E., Passoni L., Crompton T., Leu T., Schatz D., Koff A., Owen M., Hayday A. Productive T-cell receptor beta-chain gene rearrangement. coincident regulation of cell cycle and clonality during development in vivo Genes Dev. 10:1996;948-962.
29. Houldsworth J., Reuter V., Bosl G., Chaganti R. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ. 8:1997;293-299.
30. Ito Y., Takeda T., Wakasa K., Tsujimoto M., Matsuura N. Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res. 21:2001;1043-1048.
31. Kato J., Matsuoka M., Strom D., Sherr C. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol. Cell. Biol. 14:1994;2713-2721.
32. Lammie G., Fantl V., Smith R., Schuuring E., Brookes S., Michalides R., Dickson C., Arnold A., Peters G. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene. 6:1991;439-444.
33. Levelt C., Mombaerts P., Iglesias A., Tonegawa S., Eichmann K. Restoration of early thymocyte differentiation in T-cell receptor beta-chain-deficient mutant mice by transmembrane signaling through CD3 epsilon. Proc. Natl. Acad. Sci. USA. 90:1993;11401-11405.
34. Levelt C., Mombaerts P., Wang B., Kohler H., Tonegawa S., Eichmann K., Terhorst C. Regulation of thymocyte development through CD3. functional dissociation between p56lck and CD3 sigma in early thymic selection Immunity. 3:1995;215-222.
35. Liao M., Zhang X., Hill R., Gao J., Qumsiyeh M., Nichols W., Van Dyke T. No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol. Cell. Biol. 18:1998;3495-3501.
36. Lin K., Abraham K. Targets of p56(lck) activity in immature thymoblasts. stimulation of the Ras/Raf/MAPK pathway Int. Immunol. 9:1997;291-306.
37. Lukas J., Pagano M., Staskova Z., Draetta G., Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene. 9:1994;707-718.
38. Lukas J., Bartkova J., Welcker M., Petersen O., Peters G., Strauss M., Bartek J. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene. 10:1995;2125-2134.
39. Matsushime H., Ewen M., Strom D., Kato J., Hanks S., Roussel M., Sherr C. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 71:1992;323-334.
40. Matsushime H., Quelle D., Shurtleff S., Shibuya M., Sherr C., Kato J. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14:1994;2066-2076.
41. Meyerson M., Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 14:1994;2077-2086.
42. Molina T., Kishihara K., Siderovski D., van Ewijk W., Narendran A., Timms E., Wakeham A., Paige C., Hartmann K., Veillette A.et al. Profound block in thymocyte development in mice lacking p56lck. Nature. 357:1992;161-164.
43. Mombaerts P., Iacomini J., Johnson R., Herrup K., Tonegawa S., Papaioannou V. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 68:1992;869-877.
44. Mombaerts P., Anderson S., Perlmutter R., Mak T., Tonegawa S. An activated lck transgene promotes thymocyte development in RAG-1 mutant mice. Immunity. 1:1994;261-267.
45. Motokura T., Arnold A. Cyclin D and oncogenesis. Curr. Opin. Genet. Dev. 3:1993;5-10.
46. Muljo S., Schlissel M. Pre-B and pre-T-cell receptors. conservation of strategies in regulating early lymphocyte development Immunol. Rev. 175:2000;80-93.
47. Nacht M., Jacks T. V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. 9:1998;131-138.
48. Ordentlich P., Lin A., Shen C., Blaumueller C., Matsuno K., Artavanis-Tsakonas S., Kadesch T. Notch inhibition of E47 supports the existence of a novel signaling pathway. Mol. Cell. Biol. 18:1998;2230-2239.
49. Ortega S., Malumbres M., Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta. 1602:2002;73-87.
50. Ory D., Neugeboren B., Mulligan R. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA. 93:1996;11400-11406.
51. Pui J., Allman D., Xu L., DeRocco S., Karnell F., Bakkour S., Lee J., Kadesch T., Hardy R., Aster J., Pear W. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 11:1999;299-308.
52. Shaughnessy J. Jr., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Bergsagel P., Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood. 98:2001;217-223.
53. Sherr C., Roberts J. CDK inhibitors. positive and negative regulators of G1-phase progression Genes Dev. 13:1999;1501-1512.
54. -/- mice in the absence of TCR beta chain expression. Int. Immunol. 6:1994;995-1001.
55. Shinkai Y., Rathbun G., Lam K., Oltz E., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:1992;855-867.
56. Sicinski P., Liu Donaher J., Parker S., Li T., Fazeli A., Gardner H., Haslam S., Bronson R., Elledge S., Weinberg R. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 82:1995;621-630.
57. Sicinski P., Liu Donaher J., Geng Y., Parker S., Gardner H., Park M., Robker R.L., Richards J., McGinnis L., Biggers J.et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature. 384:1996;470-474.
58. Tam S., Theodoras A., Shay J., Draetta G., Pagano M. Differential expression and regulation of Cyclin D1 protein in normal and tumor human cells. association with Cdk4 is required for Cyclin D1 function in G1 progression Oncogene. 9:1994;2663-2674.
59. Tetsu O., McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell. 3:2003;233-245.
60. Weinstat-Saslow D., Merino M., Manrow R., Lawrence J., Bluth R., Wittenbel K., Simpson J., Page D., Steeg P. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med. 1:1995;1257-1260.
61. Withers D., Harvey R., Faust J., Melnyk O., Carey K., Meeker T. Characterization of a candidate bcl-1 gene. Mol. Cell. Biol. 11:1991;4846-4853.
62. Yu Q., Geng Y., Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 411:2001;1017-1021.